|
|
2325 Third Street, Suite 215
San Francisco, CA 94107 USA
phone:415.707.1281
fax:415.487.7998
|
|
| Symbol |
Private |
| Founded |
2003 |
| Employees |
15 |
|
|
| www.wave80.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Wave 80 Biosciences develops molecular diagnostic instruments and consumables for hepatitis C, B, HIV/AIDS, and other health conditions. |
|
| Management |
| Daniel Laser, Ph.D., CEO; Richard Goozh, CFO; Laura T. Mazzola, Ph.D., Senior Vice President, Global Initiatives; Andrew M. Arsham, Ph.D., Vice President, Assay Research; Amy Droitcour, Ph.D., Director, Systems Engineering |
| |
|
|
| |
|
| Keywords |
| HIVAIDS, diagnostics, hepatitis, diagnostic, molecular |
|
|
|
| Description |
|
Wave 80 Biosciences develops next-generation molecular diagnostic instruments and
consumables for hepatitis C, hepatitis B, HIV/AIDS, and other human health conditions.
The company's nucleic acid-based diagnostic technology is distinguished by a novel one
patient-one test usage model, best-in-class performance, and a superior value proposition.
In September 2009, Wave 80 was awarded a US$7.5M contract from the U.S. National
Institutes of Health for rapid HIV virus testing systems based on the company's flagship
EOSCAPE molecular diagnostics platform. Founded in 2003, the company's 15 employees work out of a
5600 square foot lab/office facility in San Francisco, California. |
|
| Products / Services |
Wave 80's molecular diagnostics products include analyzers and assay cartridges for a range of infectious diseases, oncology and autoimmune applications. The company's first products target HIV/AIDS, Hepatitis C and Hepatitis B indications.
|
|
| Technology / Differentiation |
| Wave 80's EOSCAPE systems achieve gold-standard sensitivity, reproducibility, and dynamic range with a combination of high-performance signal amplification with direct hybridization of target nucleic acids and SCA microfluidic actuators for on-cartridge sample/reagent transport and assay process enhancement. These technologies were developed over a five-year research program funded by the U.S. Special Operations Command and the National Institutes of Health. |
|
|
| Funding |
| Wave 80 has raised $12.7 million through a combination of government grants, government contracts and angel investment. |
|
| Status |
| Product development. FDA pre-IDE applications filed and testing to begin 2H 2011. Beta systems release 2012. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members